SCHEMBL3724907

SCHEMBL3724907

CC(C)=CCCC(C)C[C]=O

nearest known ligand 0.55

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 3/20 0.55
ALDH1A1 P00352 2/20 0.55
TSHR P16473 1/20 0.46
USP2 O75604 1/20 0.41
TDP1 Q9NUW8 1/20 0.38
GGPS1 O95749 2/20 0.38
FDPS P14324 2/20 0.38
GLA P06280 1/20 0.38
NFE2L2 Q16236 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL114337 0.79 ALOX15 (0.55) ALOX15ALDH1A1TSHRUSP2TDP1
SCHEMBL13279733 0.79 ALOX15 (0.55) ALOX15ALDH1A1TSHRUSP2TDP1
SCHEMBL18316483 0.79 ALOX15 (0.55) ALOX15ALDH1A1TSHRUSP2TDP1
SCHEMBL19296596 0.79 ALOX15 (0.55) ALOX15ALDH1A1TSHRUSP2TDP1
SCHEMBL27639593 0.79 ALOX15 (0.55) ALOX15ALDH1A1TSHRUSP2TDP1
SCHEMBL7134301 0.76 ALOX15 (0.57) ALOX15ALDH1A1TSHRUSP2TDP1
SCHEMBL877393 0.76 ALOX15 (0.57) ALOX15ALDH1A1TSHRUSP2TDP1
SCHEMBL9359140 0.75 ALOX15 (0.50) ALOX15ALDH1A1TSHRUSP2TDP1
SCHEMBL3696800 0.74 ALOX15 (0.58) ALOX15ALDH1A1TSHRUSP2TDP1
SCHEMBL15457016 0.74 ALOX15 (0.59) ALOX15ALDH1A1TSHRUSP2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10800790-B2 Sesquiterpenoid STAT3 inhibitors UNIVERSITY OF HAWAII (US) 2020-10-13 US claimed
JP-62019550-A None JP disclosed
US-7858349-B2 Anti-cancer compounds THE REGENTS OF THE UNIVERSITY OF COLORADO (US) 2010-12-28 US disclosed
WO-2010127381-A1 DIAGNOSIS, MONITORING, PROGNOSIS, PREVENTION AND TREATMENT OF ANEURYSMS JAMES COOK UNIVERSITY (AU) 2010-11-11 WO disclosed
US-20090088454-A1 ANTI-CANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF COLORADO (US) 2009-04-02 US disclosed
US-7427496-B2 Anti-cancer compounds THE REGENTS OF THE UNIVERSITY OF COLORADO (US) 2008-09-23 US disclosed
US-20060183772-A1 To inhibit tumor growth in an animal; to induce apoptosis NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2006-08-17 US disclosed
US-7071359-B1 Neuropathy improvers containing nitrogenous compounds as the active ingredient TEIJIN LIMITED (JP) 2006-07-04 US disclosed
EP-1201235-B1 NEUROPATHY IMPROVERS CONTAINING NITROGENOUS COMPOUNDS AS THE ACTIVE INGREDIENT TEIJIN LTD (JP) 2005-10-12 EP disclosed
EP-1201235-A1 NEUROPATHY IMPROVERS CONTAINING NITROGENOUS COMPOUNDS AS THE ACTIVE INGREDIENT TEIJIN LIMITED (JP) 2002-05-02 EP disclosed
JP-S6219550-A PRODUCTION OF MENTHONE TOYOTAMA KORYO KK 1987-01-28 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10800790-B2 Sesquiterpenoid STAT3 inhibitors STAT3, JAK2, STAT6 ALOX15 2608/4885ALDH1A1 1903/4885TSHR 3106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.